AI physiological monitoring and neural interfaces: Junction Brief – November 2026

Acentric Research is produced with AI tools under human review. It is affiliated with Acentric Capital, a private investment group whose members may hold positions in companies discussed. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief is an initial scan, not a full investigation. The method and scores behind it are in AI × Biotechnology in the Landscape Report.

Overview

Some devices read the body’s own electrical signals: a patch that follows the heart, a headset that records the brain, or an implant that picks up the activity of individual nerve cells. A recording alone is not yet a message. Software that has learned to interpret the signals can turn them into something useful, such as an alert about heart rhythm or, for a person who cannot speak, text on a screen. This Brief covers that area: artificial intelligence (AI) that interprets continuous body signals in wearable or implanted devices. It describes implanted brain-computer interfaces, the clearest case, and does not describe wearables in detail.

What stands out is how new the most advanced work is and how much of the public record comes from the companies themselves. Several developers describe implants that are being tested in people. The three described here do not describe a marketed product, and the evidence on what the implants can do comes mostly from company statements. This Brief does not show that any of these devices works.

Current state

What AI does here. A brain-computer interface records electrical activity from the brain and translates it into an action. Paradromics, a developer of such an implant, says its device sends data from implanted electrodes to a receiver in the chest, and that an external computer with advanced AI processes the data to support translation of the user’s brain activity into intended speech or computer control. Paradromics describes microelectrodes that capture activity from individual neurons (company claims). [1] Neuralink says its brain-computer interface “translates neural signals into actions” and that people in its clinical trials are using its devices to control computers and robotic arms with their thoughts (company claims). [2]

Organizations, in their own words.

  • Paradromics says it is “developing the highest data-rate brain-computer interface (BCI) platform”. On 2025-11-20 it announced that FDA had granted an Investigational Device Exemption for an early feasibility study, Connect-One, of its Connexus implant for restoring speech and computer control. The study was to enroll two participants at first, living within four hours of three clinical sites, and the company’s chief executive is quoted saying a clinical study would launch in the first quarter of 2026. [1]
  • Synchron says it is “pioneering interventional brain-computer interfaces”. It says its Stentrode implant is placed through the jugular vein, in the way a stent is placed and without cutting through the skull, and “is currently being assessed in clinical trials” in the USA and Australia. Its site states that the device is investigational and limited by federal law to investigational use. [3]
  • Neuralink describes clinical trials in which people with spinal cord injury or amyotrophic lateral sclerosis received its implant between January 2024 and April 2025, according to its site. [2]

How far it has come. The brain-computer interfaces named here are in early clinical studies and trials in people. Synchron’s site says its system is not approved for commercial use in any geography. [3] Other neural-interface developers exist, and this list is not complete. Wearable and sensor-based devices sit at a different stage: FDA’s list of authorized AI-enabled devices includes, for example, a smart sensor that estimates the probability of a heart attack, as the diagnostic devices Brief describes. [4]

Opportunities

If the early studies report safe long-term use, the evidence that these devices work in people would move from company pages to registry and journal records. Paradromics describes a roadmap to add more sites and participants to its Connect-One study. [1] None of the pages opened gives a date for results.

Challenges

  • Regulation. The implants are investigational. Paradromics describes its study as an early feasibility study, and Synchron states that its system is not approved for commercial use in any geography. [1][3]
  • Engineering. Paradromics says a preprint reported a data transfer rate of more than 200 bits per second in preclinical models, not in people (company claim). [1] Whether implanted systems stay stable and useful over years in patients is what the studies are designed to examine.
  • Evidence. No clinical result from these studies was found in the sources opened for this Brief. Neuralink’s page quotes participants and does not report study results. [2]
  • Capital and scale-up. Financing for this area was not examined for this Brief.

Data sources

  • ClinicalTrials.gov, for the registered early feasibility studies and trials of implants. [5]
  • FDA’s device databases (510(k), De Novo, premarket approval) for authorized devices. [6] FDA’s list of AI-enabled devices includes some sensor-based devices. [4] Investigational implants are mostly known through company announcements.
  • Company pages and press releases, which are the main source for implant progress and are company claims.
  • SEC EDGAR for financings by companies that file. [7]
  • NIH RePORTER, for federal grants to neural interface research. [8]

Changelog

  • 2026-11-18: First published.

Sources

  1. Paradromics, Inc., “Paradromics Receives FDA Approval for the Connect-One Clinical Study with the Connexus® Brain-Computer Interface”, 2025-11-20 (company press release). paradromics.com (accessed 2026-11-18)
  2. Neuralink, company home page (company claims). neuralink.com (accessed 2026-11-18)
  3. Synchron, Inc., company home page (company claims). synchron.com (accessed 2026-11-18)
  4. US Food and Drug Administration, “Artificial Intelligence-Enabled Medical Devices”. fda.gov (accessed 2026-11-18)
  5. National Library of Medicine, ClinicalTrials.gov. clinicaltrials.gov (accessed 2026-11-18)
  6. US Food and Drug Administration, “Medical Device Databases”. fda.gov (accessed 2026-11-18)
  7. US Securities and Exchange Commission, “Search Filings” (EDGAR). sec.gov (accessed 2026-11-18)
  8. National Institutes of Health, “RePORTER”. reporter.nih.gov (accessed 2026-11-18)